Ex­clu­sive: Af­ter Cure­Vac, Ig­or Splaws­ki moves to RTW stealth start­up; Lyn­dra's Jes­si­ca Ballinger adds CEO ti­tle amid com­mer­cial prep

A chunky chain neck­lace, match­ing ear­rings, and a flo­ral shirt with a dozen col­ors — that’s Ig­or Splaws­ki.

The for­mer chief sci­en­tist at Cure­Vac has tak­en his RNA ex­per­tise — and fash­ion — to RTW In­vest­ments’ stealth start­up Yarrow Biotech­nol­o­gy, be­com­ing its new CSO. Yarrow, just like RTW, is based in New York City. The ear­ly-stage biotech is de­vel­op­ing an­ti­sense oligonu­cleotide treat­ments for mono­genic CNS dis­eases, though it won’t dis­close ex­act­ly what in­di­ca­tions it’s look­ing at.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER